Indian pharmaceutical company Wockhardt successfully treats a US cancer patient with experimental drug Zaynich, targeting superbugs.

Indian pharmaceutical company Wockhardt announces success in treating a US cancer patient with its experimental drug Zaynich, targeting superbugs. Zaynich showed a 100% success rate in treating infections caused by drug-resistant pathogens and is undergoing a multinational Phase 3 study. Wockhardt aims to launch the novel antibiotic in India by 2024-25 and in the US and other countries by 2025-26, with a potential global market of $25 billion.

June 28, 2024
4 Articles

Further Reading